Scancell Holdings Plc Director/PDMR Shareholding (7675V)
July 25 2018 - 8:45AM
UK Regulatory
TIDMSCLP
RNS Number : 7675V
Scancell Holdings Plc
25 July 2018
25 July 2018
Scancell Holdings plc
("Scancell" or the "Company")
PDMR Dealing
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies for the treatment of cancer announces the following
director share sale and re-purchase transaction, undertaken to
satisfy a charge in relation to a SIPP.
On 24 July 2018, Dr John Chiplin sold 2,483 ordinary shares at
11 pence per ordinary share and on 25 July 2018, Dr John Chiplin
purchased 2,483 ordinary shares at 11.7 pence per ordinary share.
Following the transaction, Dr John Chiplin's total interest of
2,000,000 remains unchanged, representing 0.52% of the total voting
rights.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Dr John Chiplin
================================= ====================================
2 Reason for the notification
=======================================================================
a) Position/status Chairman and PDMR
================================= ====================================
b) Initial notification/Amendment Initial notification
================================= ====================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=======================================================================
a) Name Scancell Holdings plc
================================= ====================================
b) LEI 2138008RXEG856SNP666
================================= ====================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=======================================================================
a) Description of the Ordinary Shares of 0.1 pence each
financial instrument,
type of instrument
================================= ====================================
b) Identification Code GB00B63D3314
================================= ====================================
c) Nature of the transaction Sale of Ordinary Shares
================================= ====================================
d) Price(s) and volume(s) 2,483 Ordinary Shares
11 pence per Ordinary Share
================================= ====================================
e) Aggregated information
- Aggregated volume 2,483 Ordinary Shares
- Price 11 pence per Ordinary Share
================================= ====================================
f) Date of the transaction 24 July 2018
================================= ====================================
g) Place of the transaction London Stock Exchange, AIM
================================= ====================================
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Dr John Chiplin
================================= ====================================
2 Reason for the notification
=======================================================================
a) Position/status Chairman and PDMR
================================= ====================================
b) Initial notification/Amendment Initial notification
================================= ====================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=======================================================================
a) Name Scancell Holdings plc
================================= ====================================
b) LEI 2138008RXEG856SNP666
================================= ====================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=======================================================================
a) Description of the Ordinary Shares of 0.1 pence each
financial instrument,
type of instrument
================================= ====================================
b) Identification Code GB00B63D3314
================================= ====================================
c) Nature of the transaction Purchase of Ordinary Shares
================================= ====================================
d) Price(s) and volume(s) 2,483 Ordinary Shares
11.7 pence per Ordinary Share
================================= ====================================
e) Aggregated information
- Aggregated volume 2,483 Ordinary Shares
- Price 11.7 pence per Ordinary Share
================================= ====================================
f) Date of the transaction 25 July 2018
================================= ====================================
g) Place of the transaction London Stock Exchange, AIM
================================= ====================================
- ENDS -
For more information, please contact:
Dr John Chiplin, Chairman Scancell Holdings +44 (0) 20 3727
Dr Cliff Holloway, CEO plc 1000
+44 (0) 20 7886
Freddy Crossley/Emma Earl/Ryan McCarthy Panmure Gordon 2500
+44 (0) 20 3727
Mo Noonan/Simon Conway FTI Consulting 1000
Notes for Editors
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They can be used as
monotherapy or in combination with checkpoint inhibitors. This
platform has the potential to enhance tumour destruction, prevent
disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents. It stimulates the production of
killer CD4 T cells which overcome the immune suppression induced by
tumours, allowing activated T cells to seek out and kill tumour
cells that would otherwise be hidden from the immune system.
Moditope(R) alone, or in combination with other agents, has the
potential to treat of a wide variety of cancers.
-- Modi-1 is being developed for the treatment of triple
negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEADXSALLPEFF
(END) Dow Jones Newswires
July 25, 2018 09:45 ET (13:45 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024